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Impact of dietary-induced 
obesity on adrenergic-induced 
cardiomyocyte damage in rats
effects. Moreover, whether genetic models of marked obesity(10,11) 
exhibit cardiomyocyte apoptosis independent of conventional risk 
factors such as hypertension or diabetes mellitus, is uncertain.(12-15) 
We have recently developed an animal model of dietary-induced 
obesity without increases in blood pressure and with a normal 
blood glucose control,(16) but, in the present study we evaluated 
whether this animal model is associated with excessive cardio-
myocyte apoptosis. Obesity is a risk factor for heart failure;(1-3) 
heart failure is associated with excessive adrenergic activation;(17) 
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INTRODUCTION                                                                    
Obesity is a risk factor for heart failure independent of other 
conventional cardiovascular risk factors.(1-3) As adjustments for 
cardiac systolic chamber function abolish the relationship between 
obesity and heart failure(2) it is possible that heart failure in 
obesity is caused by pump dysfunction rather than diastolic abnor-
malities. There is increasing evidence from both human(4,5) and 
animal(6-9) studies that obesity is associated with myocardial 
contractile disturbances. These contractile disturbances may occur 
in even mild-to-moderate forms of excess adiposity.(4,5) However, 
the mechanisms responsible for this effect remain uncertain.
An increased cardiomyocyte apoptosis occurs in genetic animal 
models of marked obesity(10,11) - an effect that may in part contri-
bute toward obesity associated reductions in myocardial contrac-
tile function. However, data obtained in genetic models of 
marked obesity may not be representative of the more common 
forms of mild-to-moderate obesity that are induced by dietary 
Although obesity is an independent risk factor for heart 
failure and even mild-to-moderate forms of obesity are 
associated with myocardial systolic dysfunction the 
mechanisms of the myocardial dysfunction have not been 
identifi ed. We assessed whether dietary-induced obesity is 
associated with an increased sensitivity of the myocardium 
to -adrenergic-induced cardiomyocyte apoptosis or fi brosis. 
To induce obesity, rats were fed a diet that promotes an 
increased caloric intake. Adrenergic-induced cardiomyocyte 
apoptosis was determined by injecting rats for 5 days with 
isoproterenol (0.01 mg/kg/day for 3 days and 0.02 mg/kg/day 
for 2 days) and then studying the degree of cardiomyocyte 
damage using a TUNEL assay and assessing the pathological 
score. Five months of feeding rats a diet that promoted the 
development of an increased body weight (Control=481
±4.3 g, Diet=550±7.8 g, p<0.001) and visceral fat content 
(Control=19.6±0.8 g, Diet=33.0±1.2 g, p<0.0001), did not 
alter baseline cardiomyocyte apoptosis. However, 5 days of 
-adrenergic activation resulted in an enhanced cardio-
myocyte apoptosis in rats receiving the experimental diet 
as compared to rats receiving a normal diet (p<0.01). No 
changes in the myocardial pathological score (fi brosis) were 
noted. The enhanced adrenergic-induced cardiomyocyte 
apoptosis in obese rats could not be explained by dietary-
induced increases in baseline left ventricular internal dia-
meters, decreases in systolic function (endocardial or midwall 
fractional shortening) or differences in the response of the 
heart to adrenergic-induced increases in inotropic or chrono-
tropic function. In conclusion, the present study suggests 
that obesity may contribute to myocardial dysfunction by 
increasing the sensitivity of the myocardium to adrenergic-



















and adrenergic activation is a well-recognised stimulus for 
cardiomyocyte apoptosis;(18) we therefore also explored the possi-
bility that dietary-induced obesity increases the susceptibility of 
the myocardium to -adrenergic agonist-induced cardiomyocyte 
apoptosis.
METHODS                                                                                  
Study groups
The present study was approved by the University of the 
Witwatersrand Animal Ethics Screening Committee (approval 
numbers: 2006/59/04 and 2006/99/03) and complies with the 
National Institutes of Health Guide for the Care and Use of 
Laboratory Animals. Dietary-induced obesity was produced by 
feeding Wistar-Kyoto rats an experimental diet (n=30) recently 
described(16) which consists of 65% carbohydrate, 19% protein, 
and 16% fat in comparison to that of a control diet (n=30) which 
consists of 60% carbohydrate, 30% protein, and 10% fat. As the 
experimental diet is designed to induce hyperphagia(16) the 
experimental groups consumed a greater quantity of food than 
the animals fed the control diet and, consequently, energy intake 
was enhanced in the experimental groups (570±23 kJ/day) 
compared to the control group that consumed 371±18 kJ/day. 
Our research groups have previously shown that differences in 
micronutrient (vitamins and minerals) intake produced by dilution 
of the diet by addition of carbohydrates and fats does not modify 
either body size or cardiac structure or function.(16) After 5 months 
of feeding the different diets, rats were randomly assigned to 
receive either the -adrenoreceptor agonist, isoproterenol (ISO) 
(0.01 mg/kg/day for 3 days and 0.02 mg/kg/day for 2 days)(18) 
(Diet-ISO, n=14; Control-ISO, n=14) or the saline vehicle (Diet-
Saline, n=16; Control-Saline, n=16). Isoproterenol was constituted 
in sterile saline (0.9% NaCl) in order that each rat would receive 
subcutaneous injections of ~0.1-0.2 ml volumes daily. Control 
rats received daily injections of sterile saline at the same volume.   
Blood pressures, blood glucose control and assessment of 
adiposity
Non-invasive tail cuff blood pressures(15) were measured at the 
beginning and at the end of the study in all rats to confi rm the 
previously described lack of effect of the experimental diet on 
blood pressure.(16) The percentage glycosylated haemoglobin 
(HbA1c) was determined to confi rm the previously described 
normal blood glucose control in the experimental diet fed rats.(16) 
HbA1c was determined in blood samples obtained from the 
thoracic cavity immediately after extirpation of the heart, using 
the HBA1CII Tina-Quant kit (Cobas-Roche Diagnostics). Body 
weights were recorded in rats before the start of feeding and 
then once a month at the same time on the same day of each 
week until the end of the study. At the end of the study, visceral 
fat weight was determined post-mortem. To weigh visceral fat, 
fat was removed from the retroperitoneal space on the posterior 
wall of the abdominal cavity and from the omentum.
Echocardiography
At the end of the study left ventricular systolic function and 
chamber dimensions were determined in vivo as previously 
described(19) in anaesthetised rats (50 mg/kg of ketamine and 3 mg/
kg of xylazine) before and 15 minutes after an acute injection of 
isoproterenol at the doses administered to rats to induce 
cardiomyocyte apoptosis. In this component of the study 8 rats 
from each of the saline-treated groups and 10 rats from each of 
the ISO groups were randomly selected. Left ventricular end-
diastolic (LVEDD) and end-systolic (LVESD) internal diameter and 
end-diastolic (ED PWT) and end-systolic posterior wall thickness 
(ES PWT) were measured with two-dimensional targeted M-
mode echocardiography (7.5 MHz transducer and a Hewlett 
Packard Sonos 2500 sector scanner). Left ventricular chamber and 
myocardial systolic function were determined from endocardial 
(FSend) and midwall (FSmid) fractional shortening respectively, 
as previously described.(19) The following formulae were employed 
to determine FSend and FSmid:
FSend = EDD-ESD/EDD x 100
FSmid = [(EDD+ED PWT)/2-(ESD+ES PWT)/2]  x 100
                           (EDD+ED PWT)/2
Cardiomyocyte fi brosis and apoptosis
After echocardiography in those rats in which echocardiography 
was performed (Diet-ISO, n=10; Diet-Saline, n=8; Control-ISO, 
n=10; Control-Saline, n=8), and in the remaining rats (Diet-ISO, 
n=4; Diet-Saline, n=8; Control-ISO, n=4; Control-Saline, n=8), the 
heart was removed from the thoracic cavity under anaesthesia 
and weighed. Left ventricular tissue was stored in formalin, pro-
cessed routinely for light microscopy and 50 μm thick sections of 
the long axis circumference cut through the full thickness of the 
left ventricular wall. Ten slices were obtained at 1 mm intervals 
and stained with van Gieson’s stain. After staining, a pathological 
grade was assigned, where 0 indicates no damage; 1 and 2, patchy 
fi brosis in less than or more than 20% of the fi eld respectively; 
3 and 4, diffuse contiguous subendocardial fi brosis in less than 
or more than 50% of the fi eld respectively and 5 and 6, full 
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thickness fi brosis in less than or more than 50% of the fi eld 
respectively.(20)
The degree of apoptosis was quantifi ed as previously des-
cribed(18,21) on 5 μm thick myocardial tissue sections obtained from 
the same tissue blocks used to assess the pathological score. 
Nuclear deoxyribonucleic acid (DNA) fragments in the tissue 
sections were detected using a non-radioactive in situ apoptotic 
cell death detection kit (DeadEndTM Colorimetric TUNEL system, 
Promega, Madison, WI, USA), where terminal deoxynucleotidyl 
transferase (TdT) was used to incorporate biotinylated nucleotide 
at the 3’-OH DNA ends. The number of apoptotic cardiomyocyte 
nuclei and the total number of cardiomyocyte nuclei (haematoxylin 
and eosin stain) in each slide were counted on ten evenly spaced 
fi elds from the apex to the base using a computer-based image 
acquisition and analysis system at 400 times magnifi cation (Axio-
vision 3, Carl Zeiss, Gottingen, Germany). Apoptotic cardiomyo-
cyte nuclei were expressed as a percentage of the total number 
of cardiomyocyte nuclei.
Data analysis
All data are presented as mean±SEM. Comparisons between 
groups were made with a two-way ANOVA or with a Student’s 
t-test when pooled analysis was performed.
RESULTS                                                                               
Measures of excess adiposity
Figure 1 shows the effect of the experimental diet on body weight. 
The experimental diet resulted in a 15% increase in body weight 
and a 74% increase in visceral fat weight (Control diet=19.6±0.8 g, 
Experimental diet=33.0±1.2 g, p<0.0001) as compared to control 
diet fed rats. The body weight in rats receiving the experimental 
diet was statistically greater than the body weight in rats receiving 
the control diet, from the fourth month of the study (Figure 1). 
Importantly, similar dietary effects on body weight and visceral 
fat were noted in rats assigned to receive either isoproterenol or 
the vehicle at the end of the study period (data not shown).
Blood pressures and percentage glycosylated haemoglobin
Dietary-induced obesity had no effect on tail-cuff systolic blood 
pressure (Experimental diet: Baseline=116±3 mm Hg: After 5 
months of the study=118±4 mm Hg; Control diet:  Baseline=112
±4 mm Hg: After 5 months of the study=119±4 mm Hg). 
In addition, the obesity-inducing diet did not infl uence the percen-
tage glycosylated haemoglobin (Experimental diet=4.69±0.13%, 
Control diet=4.68±0.05%).   
Impact of obesity and short-term adrenergic stimulation on 
heart weight
As compared to the control diet fed groups a trend for an 
increase in heart weight and left ventricular weight was noted in 
the experimental diet fed groups (Table 1). In a pooled analysis 
of all control diet fed as compared to all experimental diet fed 
rats, the experimental diet resulted in an increase in heart 
weight (Experimental diet=1.23±0.02 [n=30], Control diet=1.14
±0.02 [n=30], p<0.005) and left ventricular weight (Experi-
mental diet=1.01±0.02, Control diet=0.94±0.02, p<0.005). Short 
term isoproterenol administration failed to modify heart weight 
or left ventricular weight in the control or the experimental diet 
groups as compared to their respective control groups (Table 1). 
Moreover, isoproterenol failed to modify heart weight or left 
ventricular weight in pooled analysis comparing data obtained in 
all rats receiving isoproterenol versus all rats receiving the vehicle 
(data not shown). In a comparison of the four groups, left ventri-
cular weight was greater in the experimental diet group receiving 
isoproterenol as compared to the two control diet fed groups 
(Table 1). As the experimental diet resulted in a greater increase 
in body weight (~15%) as compared to heart (~8%) or left 
ventricular weight (~7%) a decrease in the heart and left ventri-
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FIGURE 1: Changes in body weight over time in rats receiving 
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cular weight-to-body weight ratios was noted in the experimental 
diet fed groups.
Impact of obesity and short-term adrenergic stimulation on 
left ventricular systolic function, heart rate and chamber 
dimensions
Figure 2 shows left ventricular systolic chamber and myocardial 
function and heart rate in rats at the end of the study and 
inotropic and chronotropic responses to acute administration 
of isoproterenol. Neither the experimental diet given for 5 
months, nor 5 days of isoproterenol administration modifi ed 
baseline left ventricular chamber or myocardial systolic function or 
heart rate. What is more,  neither the experimental diet nor 
isoproterenol administration modifi ed inotropic or chronotropic 
responses to acute isoproterenol administration.
In a pooled analysis of all experimental diet fed rats as compared 
to all control diet fed rats, the experimental diet tended to 
increase left ventricular wall thickness (Experimental diet=1.96
±0.06, Control diet=1.83±0.04, p=0.07) but did not modify left 
ventricular internal dimensions (Experimental diet=8.54±0.12, 
Control diet=8.44±0.17, p=0.65). Table 2 shows LV internal 
dimensions and wall thickness in the 4 groups of rats at the end 
of the study. Neither the experimental diet given for 5 months, 
nor 5 days of isoproterenol administration modifi ed either LV 
internal dimensions or wall thickness.
Impact of obesity and isoproterenol on cardiomyocyte 
apoptosis and fi brosis
Figure 3 shows the effect of isoproterenol given for 5 days as 
well as the experimental diet on the percentage TUNEL positive 
stained cardiomyocyte nuclei and the pathological score of the 
left ventricle. The experimental diet alone failed to increase the 
TABLE 1: Cardiac morphometry in rats fed different diets for 5 months 
and subsequently receiving either isoproterenol (ISO) or the saline vehicle 
for 5 days.
HW, heart weight; LVW, left ventricular weight; BW, body weight; Control, control diet; Diet, 
experimental diet.  *p<0.05 versus both control diet fed groups;  **p<0.01 versus respective 
control diet fed groups.
 HW (g) LVW (g) HW/BW LVW/BW 
Control-Saline (n=16) 1.13±0.02 0.94±0.02 2.35±0.05 1.95±0.04
Control-ISO (n=14) 1.15±0.03 0.95±0.03 2.39±0.06 1.96±0.05
Diet-Saline (n=16) 1.19±0.03 0.98±0.02 2.20±0.05 1.82±0.04**
Diet-ISO (n=14) 1.26±0.03 1.04±0.02* 2.26±0.03 1.85±0.02**
FIGURE 2: Effect of acute isoproterenol (ISO) administration on 
left ventricular systolic chamber (endocardial fractional shortening, 
FSend) and myocardial (midwall fractional shortening, FSmid) 
function as well as heart rate (HR) in rats receiving a normal diet 
(Control) or a diet designed to increase caloric intake (Diet). 
Saline, receiving the saline vehicle of ISO.  
Baseline               After acute ISO



























































proportion of TUNEL positive stained cardiomyocyte nuclei. 
However, despite the inability of isoproterenol to signifi cantly 
increase the proportion of TUNEL positive stained cardiomyo-
cyte nuclei in control diet fed rats, rats fed the experimental diet 
developed an increase in the proportion of TUNEL positive 
stained cardiomyocyte nuclei as compared to all other groups. 
Importantly, neither the experimental diet nor isoproterenol 
affected the myocardial pathological score. Only minimal fi brosis 
(ranging from grades 0 to 3) was noted in each of the groups. 
DISCUSSION                                                                      
The main fi nding of the present study is that the myocardium 
of obese rats is more sensitive to the myocardial apoptotic effects 
that occur in response to adrenergic stimulation. The enhanced 
adrenergic-induced cardiomyocyte apoptosis in obese rats could 
not be explained by dietary-induced increases in baseline left 
ventricular internal diameters, decreases in systolic function 
(endocardial or midwall fractional shortening) or differences in 
the response of the heart to adrenergic-induced increases in 
inotropic or chronotropic function.
Previous studies have demonstrated that an increased cardio-
myocyte apoptosis accompanies severe obesity in genetic animal 
models.(10,11) In this regard, the present study supports the notion 
that obesity may promote cardiomyocyte apoptotic effects even 
in mild-to-moderate forms of obesity, albeit that this effect is only 
noted in the presence of an adrenergic stimulus. In the present 
study, the lack of ability of obesity per se to promote excessive 
cardiomyocyte apoptosis in the absence of an adrenergic stimulus 
may be accounted for by the relatively modest increase in body 
weight produced by the model studied (body weights ~15% 
greater than lean animals). This is in contrast to previous studies 
reporting on obesity-induced effects on cardiomyocyte apoptosis 
in the absence of an exogenous stimulus such as a -adreno-
ceptor agonist(10,11) in genetic rodent models of obesity associated 
with considerably greater increases in body weights (~45 to 84% 
greater than lean animals)(11,22) than those reported on by us. In 
this regard however, the present study is more likely to refl ect 
the predominant form of obesity that occurs at a population 
level (mild-to-moderate) in contrast to previous animal studies 
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TABLE 2: Comparison of left ventricular diameters and wall thickness 
values in rats fed different diets for 5 months and subsequently receiving 
either isoproterenol (ISO) or the saline vehicle for 5 days.
LVEDD, Left ventricular end diastolic diameter ; LVESD, LV end systolic diameter ; PWTed, LV 
end diastolic posterior wall thickness; PWTes, LV end systolic posterior wall thickness Control, 
control diet; Diet, experimental diet.
 LVEDD LVESD PWTed PWTes
 (mm) (mm) (mm) (mm) 
Control-Saline (n=8) 8.46±0.18 4.96±0.19 1.87±0.06 2.73±0.13
Control-ISO (n=10) 8.43±0.28 4.99±0.23 1.79±0.06 2.68±0.09
Diet-Saline (n=8) 8.45±0.22 4.59±0.24 1.98±0.13 3.02±0.14

















FIGURE 3: Impact of an experimental diet designed to increase 
caloric intake (Diet) as compared to a normal diet (Control) on 
the effects of 5 days of -adrenergic stimulation with isoproterenol 
(ISO) on the percentage TUNEL stained cardiomyocyte nuclei 
(Apoptosis) and the pathological score of the myocardium. Saline, 
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that are more likely to refl ect the impact of more severe forms of 
obesity on the myocardium.(10,11)
In contrast to previous studies(10,11) where it is uncertain whether 
the obesity-associated cardiomyocyte apoptotic effect occurs 
independently of alternative conventional risk factors such as 
hypertension or diabetes mellitus,(12-15) in the present study we 
show that obesity is associated with adrenergic-induced 
cardiomyocyte apoptosis in a model without increases in blood 
pressure or alterations in blood glucose control (glycosylated 
haemoglobin) and in a model which we have previously reported 
to be euglycaemic.(16) Thus, the present study is the fi rst to show 
that mild-to-moderate adiposity promotes cardiomyocyte apop-
tosis independent of blood pressure or blood glucose control. 
Importantly, however, this effect requires excessive adrenergic 
activation, a change that often accompanies obesity.(23)
In the present study the mechanisms of the increased suscepti-
bility of the myocardium in obese rats to adrenergic-induced 
cardiomyocyte apoptosis were not identifi ed. However, a few 
possibilities were considered. First, as the degree of obesity 
produced in rats in the present study promoted mild increases 
in left ventricular mass, it is possible that cardiac hypertrophy, 
which is a well-recognised risk factor for cardiomyocyte apoptosis,(24) 
can explain the obesity-associated increase in adrenergic-induced 
cardiomyocyte apoptosis. Second, increases in myocardial reactive 
oxygen species, previously shown to mediate cardiomyocyte 
apoptosis(25) and produced by increments in cardiac wall stress 
need to be considered. In this regard, although we did not 
measure myocardial wall stress, it is unlikely that this mechanism 
plays a signifi cant role, as resting systolic blood pressures and 
left ventricular chamber dimensions were unchanged, and adre-
nergic-induced inotropic and chronotropic responses in obese 
rats were comparable to those of lean rats. However, as myo-
cardial -adrenergic stimulation promotes the generation of 
reactive oxygen species,(26) further studies are required to assess 
whether obese rat hearts are more susceptible to adrenergic-
induced increases in the production or effects of reactive oxygen 
species. Importantly, it is unlikely that the increased adrenergic-
induced cardiomyocyte apoptosis in obese rats can be explained 
by a combination of exogenous adrenergic actions and increased 
endogenous sympathetic effects, as this model of obesity is not 
associated with increases in endogenous norepinephrine release.(16) 
Third, in genetic animal models, obesity-induced cardiomyocyte 
apoptosis may also be mediated by the accumulation of tri-
glycerides in the heart.(11) In this regard, a combination of peri-
pheral lipolysis induced by catecholamines and a decrease in the 
expression of myocardial enzymes responsible for fatty acid 
oxidation is thought to produce this effect.(11) It is therefore 
possible that in the present study, obesity promoted a reduction in 
myocardial fatty acid oxidation, whilst the exogenous adrenergic 
stimulus produced lipolysis, the overall effect being an increase in 
cardiomyocyte apoptosis. Further work is required to explore 
this possibility.
Although caution should be exercised in translating these data to 
the clinical scenario, some possible clinical implications can be 
considered. As obesity is a risk factor for heart failure(1-3) and 
heart failure is associated with excessive adrenergic activation(17) 
it is important to consider the combination of these effects. 
The present data suggest that this combination mediates a 
synergistic effect to promote cardiomyocyte apoptosis. As cardio-
myocyte apoptosis may have a causal role to play in the patho-
physiology of ventricular dysfunction and its progression to cardiac 
failure,(27,28) the present data suggest that myocardial decompen-
sation in obese patients with heart failure may progress more 
rapidly than in lean patients unless appropriate adrenergic blockade 
is employed. 
The limitations of the present study are as follows. First, the 
modest degree of obesity produced may have limited the out-
comes of the present study. However, employing a model of 
modest as opposed to severe obesity is nevertheless entirely 
consistent with the high prevalence of mild-to-moderate obesity 
which presently exists world-wide, whilst more severe forms of 
obesity are less common. Further, by studying a more modest 
model of obesity, we biased the outcomes against ourselves, 
thus rendering our ability to show an impact of obesity on 
cardiomyocyte apoptosis even more impressive. Second the 
technique used to detect cardiomyocyte apoptosis (TUNEL 
technique) may overestimate the number of apoptotic nuclei, as 
it labels both DNA fragmentation and cells undergoing DNA 
repair. Alternative techniques such as the assessment of myo-
cardial caspase-3 activity or other methods could have been 
employed to support the present outcomes. However, the 
assessment of myocardial caspase-3 activity requires freeze 
clamped tissue, the collection of which would have precluded 
the assessment of heart and left ventricular weights and the 
histological evaluation of apoptosis. 
In conclusion, the results of the present study indicate that mild-
to-moderate obesity is associated with an increased susceptibility 
160
of the myocardium to adrenergic-induced cardiomyocyte apop-
tosis independent of changes in blood pressure, left ventricular 
dilatation or alterations in adrenergic-induced inotropic and 
chronotropic responsiveness. These fi ndings cast further light on 
the mechanisms that may explain the independent relationship 
between obesity and the development of heart failure(1-3) and 
suggest that obesity may hasten the progression of cardiac 
decompensation in heart failure unless appropriate adrenergic 
blockade is employed. Clinical studies are required, conducted in 
obese and lean patients with comparable degrees of cardiac 
dysfunction and sympathetic activation at baseline, to address 
this issue. 
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